Silas Inman


Drug Development May Speed Up Thanks to New Research Methods

July 26, 2019

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.

Next-Generation BCMA CAR T-cell Therapy Effective for Heavily Pretreated Myeloma

January 01, 2019

The anti-BCMA CAR T-cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma, according to initial results from a phase I study presented at the 2018 ASH Annual Meeting.

FDA Approves Moxetumomab Pasudotox for Hairy Cell Leukemia

September 14, 2018

The FDA has approved the CD22-directed recombinant immunotoxin moxetumomab pasudotox (Lumoxiti) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior lines of therapy, including treatment with a purine nucleoside analog.

Liso-Cel Shows Promise in High-Risk Diffuse Large B-Cell Lymphoma

June 07, 2018

A promising CD19-directed chimeric antigen (CAR) T-cell therapy, Lisocabtagene maraleucel (JCAR017; liso-cel), may result in durable remissions among patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.